Wednesday, November 21, 2012

Avastin® (Bevacizumab) Stalls Most Common And Most Aggressive Brain Cancer For Over Four Months Long

Adding Avastin to the current standard of care for newly diagnosed aggressive brain cancer (glioblastoma multiforme, GBM) can significantly extend the time people live without their disease worsening, by 4.4 months (progression free survival of 10.6 months compared to 6.2 months with radiation and chemotherapy plus placebo, HR =0 ...





No comments:

Post a Comment